News >

FDA Approves Third Daratumumab Triplet for Myeloma

Jason M. Broderick @jasoncology
Published: Friday, Jun 16, 2017

Jan van de Winkel, PhD

Jan van de Winkel, PhD

The FDA has approved daratumumab (Darzalex) for use in combination with pomalidomide (Pomalyst) and dexamethasone for patients with multiple myeloma who have received at least 2 prior therapies, including a proteasome inhibitor and lenalidomide (Revlimid).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x